ClinicalTrials.gg
Active, not recruitingNCT06153862ARMSUpdated Dec 1, 2023

Africa Ready Malaria Screening

An interventional study of Immuno analytical assay in Malaria, sponsored by University of Ghana. Active, not recruiting at 1 site in Ghana. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by University of Ghana · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as active, not recruiting.
  • Registered 6 months after the study started (first participant enrolled Sep 2022, registered Mar 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,640
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Malaria with a site in Ghana — 5 open to participants now, 6 under way, none of them phase 3. Malaria · Ghana.

Enrollment
22nd of 47
1,640 · median 1,490
Started
2022
the only one that year
No phase
14 of 59
2 open now
Registered
55th of 59
by date
Lead sponsor
2 of 59
University of Ghana

Among the 59 studies in Malaria with a site in Ghana, this one is the 22nd largest by enrollment of the 47 interventional ones that give a count, is the only one that started in 2022, is one of 14 with no phase, and was the 55th registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

5 of the 59 studies in Malaria with a site in Ghana are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Ghana have not opened yet or have stopped. Only those recruiting at a site in Ghana →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Malaria with a site in Ghana, or all of them as a file.
02

Study summary

This study aims to develop immuno-analytical assays for testing the titres of malaria antibodies in Ghanaian patients' and/or donors' sera using a recombinantly produced MSP119 fusion protein and/or MSP119-derived synthetic peptides as antigens.

Read the detailed description

In this study, immuno-analytical assays will be developed for determining the titres of malaria antibodies in sera of two groups (malaria patients and donors/healthy volunteers) using a recombinantly produced MSP119 fusion protein and/or MSP119-derived synthetic peptides as antigens. Individuals in the two groups presenting to Shai-Osudoku District hospital will be screened for signs and symptoms of malaria according to the WHO criteria. Those within the inclusion and exclusion criteria will be introduced to the study through informed consent for adults (18 years and over) or parents/guardians for children below 12 years and assent for adolescents between 12 and below 18 years, along with informed consent from their parents. Enrolled study participants' demographic data and vital signs will be captured electronically onto the CRF. Patients will have their clinical history and detailed physical examination done by the study clinicians and then be sent to the laboratory for investigations to confirm the malaria diagnosis. The results of patients will be communicated to the study clinician to commence the appropriate treatment. At the of the study, the results of all assays will be analyzed to determine if this test can be used to diagnose malaria infection.

03

Conditions studied

  • Malaria

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with confirmed malaria (uncomplicated and complicated cases) are diagnosed by the national guidelines.
  • Healthy individuals without confirmed malaria per the national guidelines.
  • Adults and parents or guardians of children below 12 years willing to participate based on signed .
  • Willing to give assent to adolescents between the ages of 12 and below 18 years.
  • Willing to give a blood sample for the necessary investigations as explained in the informed consent.
  • Willing to adhere to study procedures and a follow-up visit at the clinic, hospital, or health facility.

Exclusion criteria

Exclusion Criteria:

  • Anyone refusing (or assent for adolescents) to be part of the study.
  • Refusal to study procedures or giving of sample for the necessary investigations.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,640 participants (actual)

Study arms

  • Active comparator
    Malaria patients

    Malaria patients

    Diagnostic Test: Immuno analytical assay

  • Active comparator
    Non malaria donors

    Healthy individuals (donors; controls)

    Diagnostic Test: Immuno analytical assay

Interventions

  • Diagnostic testImmuno analytical assay

    The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.

06

What researchers measure

Primary outcomes

  1. MSP1-19 malaria antigen

    Number of participants with MSP1-19 malaria antigen as assessed by a lateral flow test kit.

    Time frame: one year

Secondary outcomes

  1. Anti-MSP1-19 malaria antibody

    Number of participants with antiMSP1-19 malaria antibody as assessed by a lateral flow test kit.

    Time frame: three years

07

Study locations

1 site
  • Shai-Osudoku District Hospital
    Dodowa, Outside North America GAR, Ghana
08

References and documents

Individual participant data

Plan to share: Yes — Data will be deposited in Zenodo's open data repository service (CERN). Additionally, all datasets will be stored on external drives and in-house computers. The data will be deposited as soon as possible unless there is a legitimate reason and a decision has been agreed upon to protect the data. Before the upload of datasets, a unique DOI will be assigned, which will be stated in publications to direct readers to the primary datasets. Due to the public health interest of the outcome of this work, the datasets will be shared directly with relevant stakeholders for a wider public audience. There will be restricted datasets on the subject partaking in the study to protect their identity. This restriction will not affect the dissemination of the research outputs to the broader public. Although the datasets will be stored in the Zenodo repository for long-term preservation, the in-house datasets will be stored on an external drive for additional long-term benefit.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Five years

Access criteria: The IPD can be accessed by requesting the Principal Investigator or accessing the information directly from Zenodo's open data repository service.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Sep 2024, 24 months after the start.

Of 96 non-industry interventional studies with no phase under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 24 months is close to that.

Counting every sponsor, half of 102 studies reached it within 23 months; a quarter within 8 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2023
First posted
Dec 1, 2023
StartActual
Sep 23, 2022
Primary completionEst.
Sep 2024
CompletionEst.
Sep 2025
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06153862
Lead sponsor
University of Ghana
Collaborators
Shai-Osudoku District Hospital, Kumasi Technical University, University of Rostock, University of Applied Sciences Bonn-Rhein-Sieg, Hochschule Aalen
Responsible party
Prof. Kwabena F.M. Opuni (Associate Professor, University of Ghana) — Principal investigator
First posted
Dec 1, 2023
Start date
Sep 23, 2022
Primary completion
Sep 2024 (estimated)
Completion
Sep 2025 (estimated)
Last update
Dec 1, 2023

Study contacts

Adjei
study director · Shai-Osudoku District Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion